Phase I Open Label study of Onconase [ranpirnase] administered on days 1 and 4 weekly for three consecutive weeks of a 28 day cycle in subjects with advanced solid malignancies
Latest Information Update: 14 Jan 2008
At a glance
- Drugs Ranpirnase (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 14 Jan 2008 Status change
- 18 Dec 2007 New trial record.